Skip to content

Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)

Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02219958
Enrollment
2496
Registered
2014-08-19
Start date
2012-09-30
Completion date
2017-04-30
Last updated
2017-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension

Brief summary

Hypertension (HT) is one of the major cause of morbidity and among the top 10 causes of deaths in Hong Kong in 2008 (Department of Health 2009). The Hospital Authority (HA) has initiated service improvement through introducing the risk assessment and management programme (RAMP) to improve the quality of care (QOC) for HT patients in general outpatient clinics (GOPC). The evaluation on the QOC is an essential part of the programme in order to inform future policy. The Department of Family Medicine and Primary Care (FMPC) of the University of Hong Kong (HKU) has been appointed by the HA to carry out the evaluation of the QOC of the programme. The Action Learning and Audit Spiral methodologies to measure whether the target standard of care intended by the RAMP programme is achieved. Each RAMP participating clinic and hospital will be invited to complete a structured evaluation questionnaire. The data of all patients who have enrolled into the RAMP for more than one year will be included in the evaluation on the process and outcomes of care. One thousand two hundred and forty-eight age and disease matched control patients who have not been enrolled into the RAMP programme will be selected for the comparison in the outcomes of care. A hundred and thirty participants will be followed up by telephone to evaluate the effect of the programme in quality of life (QOL), patient enablement, and global rating of change in health condition at baseline and 6 months after enrolment. Data on the process of care will be retrieved from the HA medical records. Main Outcome Measures: The primary outcomes are the proportion of participants who have received the criterion process of care, and achieved the target blood pressure levels. Data Analysis: Descriptive statistics on proportions of centers or subjects meeting the QOC criteria will be calculated. The changes in the clinical and patient reported outcomes of RAMP subjects will be compared at 12, 24, 36 and 48 months will be compared by paired sample t-test. The clinical outcomes between RAMP subjects and control group will be compared by independent sample t-test or Chi-square test. Results: The QOC of the RAMP programme will be determined. Areas of deficiency and possible areas for quality enhancement will be identified. Conclusion: The results of this study will provide empirical evidence on whether the HA's RAMP programme can achieve improvement in QOC for HT patients. The information will be used to guide service planning and policy decision making.

Interventions

None listed

Sponsors

Hospital Authority, Hong Kong
CollaboratorOTHER_GOV
The University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HT * aged \<80 * Suboptimal BP control (average systolic blood pressure (SBP) ≥ 140mmHg or average diastolic blood pressure (DBP) ≥ 90mmHg)

Exclusion criteria

* Patients will be excluded if they are unable to understand or communicate in Chinese language, or refuse to give consent. * Patients will be excluded if they had prior history of diabetes and existing cardiovascular diseases

Design outcomes

Primary

MeasureTime frameDescription
The proportion of clinics that have satisfied each of the structure criteriaThree yearsFinal analysis will evaluate the period from August, 2012 to December, 2014.
The proportion of patients who have complied with the criterion process of care.Three yearsFinal analysis will evaluate the period from August, 2012 to December, 2014.
The proportion of patients who have achieved a BP level <140/90mmHg.Three yearsFinal analysis will evaluate the period from August, 2012 to December, 2014.

Secondary

MeasureTime frameDescription
The change in SF-12v2 scoresThree yearsBaseline and 6-month/12-month/24-month/36-month after the first administration of questionnaire.
LDLThree yearsBaseline and 12 months for each subject; the audit cycle will be repeated annually over a period of 3 years.
GRS (Global Rating of Change Scale) scoresThree years6-month/12-month/24-month/36-month after the first administration of questionnaire.
PEI (Patient Enablement Index)Three years6-month/12-month/24-month/36-month after the first administration of questionnaire.
BMI (Body Mass Index)Three yearsBaseline and 12 months for each subject; the audit cycle will be repeated annually over a period of 3 years.
Occurrence of First Cardiovascular ComplicationThree yearsBaseline and 12 months for each subject; the audit cycle will be repeated annually over a period of 3 years.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026